Changeflow GovPing Pharma & Drug Safety NIR-II photothermal material reverses cancer mu...
Routine Notice Added

NIR-II photothermal material reverses cancer multidrug resistance

Email

Summary

NIR-II photothermal material reverses cancer multidrug resistance

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

USE OF NIR-II PHOTOTHERMAL MATERIAL IN PREPARATION OF DRUG FOR REVERSING MULTIDRUG RESISTANCE OF CANCER CELLS

Publication EP2023169546A1 Kind: A1 Mar 25, 2026

Applicants

South China University of Technology

Inventors

The designation of the inventor has not yet been filed

IPC Classifications

A61K 41/00 20200101AFI20230915BHEP A61K 9/14 20060101ALI20230915BHEP A61K 47/24 20060101ALI20230915BHEP A61P 35/00 20060101ALI20230915BHEP C07D 513/04 20060101ALI20230915BHEP C09K 11/06 20060101ALI20230915BHEP A61K 47/69 20170101ALI20230915BHEP A61K 47/59 20170101ALI20230915BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Instrument
Notice

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.